Clinical trial · Observational
Exendin PET/CT for Imaging of Paragangliomas
Exendin PET/CT for Paragangliomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Functional imaging of paragangliomas (PGLs) is not unequivocal. Existing functional imaging modalities show good but variable results in PGLs, warranting the search for additional molecular imaging targets. Investigators aim to evaluate the glucagon-like peptide 1 receptor (GLP-1R) as a novel target for molecular imaging of PGLs. For this purpose investigators will use the tracer 68Ga-NODAGA-exendin 4 for positron emission tomography/computed tomography (PET/CT) imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Paraganglioma | Paraganglioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-NODAGA-exendin-4 PET/CT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with confirmed paraganglioma
- description
- 10 patients with confirmed PGL who have undergone CT, somatostatin receptor (SSTR) PET/CT and 18F-FDG PET/CT (as standard diagnostic procedures) and are scheduled for surgery.
- interventionNames
- Radiation: 68Ga-NODAGA-exendin-4 PET/CT
Primary outcomes (1)
- measure
- detection rate of PGL's using 68Ga-exendin-4 PET/CT
- timeFrame
- 1 year
- description
- Detection based on visual inspection of PET/CT images
Secondary outcomes (1)
- measure
- optimal timepoint for imaging PGLs using 68Ga-exendin-4 PET/CT
- timeFrame
- After inclusion of the first 5 patients (up to 6 months)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Proven sympathetic PGL with a single tumor detected using standard diagnostic imaging * No evidence of metastatic disease * CT, SSTR PET/CT and 18F-FDG PET/CT performed (golden standard diagnostic imaging) * Scheduled for surgery * Able to sign informed consent Exclusion Criteria: * Breast feeding * Pregnancy or the wish to become pregnant within 1 month * Calculated creatinine clearance below 40ml/min * Evidence of other malignancy than PGL in conventional imaging (suspicious liver, bone and lung lesions) * Age \< 18 years * Not able to sign informed consent
References
Publications (0)
Data not yet available